CIBC World Markets’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $3.24M | Buy |
+18,667
| New | +$3.4M | 0.02% | 513 |
|
|
2025
Q2 | $2.52M | Buy |
14,049
+633
| +5% | +$110K | 0.02% | 514 |
|
|
2025
Q1 | $2.27M | Sell |
13,416
-4,204
| -24% | -$691K | 0.02% | 470 |
|
|
2024
Q4 | $2.66M | Buy |
17,620
+2,489
| +16% | +$387K | 0.02% | 488 |
|
|
2024
Q3 | $2.35M | Buy |
15,131
+824
| +6% | +$123K | 0.02% | 489 |
|
|
2024
Q2 | $1.96M | Buy |
14,307
+3,111
| +28% | +$426K | 0.01% | 503 |
|
|
2024
Q1 | $1.49M | Sell |
11,196
-3,276
| -23% | -$425K | 0.01% | 578 |
|
|
2023
Q4 | $2M | Buy |
14,472
+8,277
| +134% | +$1.09M | 0.01% | 519 |
|
|
2023
Q3 | $755K | Sell |
6,195
-6,936
| -53% | -$924K | 0.01% | 523 |
|
|
2023
Q2 | $1.85M | Buy |
13,131
+7,518
| +134% | +$1.04M | 0.02% | 471 |
|
|
2023
Q1 | $794K | Sell |
5,613
-7,776
| -58% | -$1.11M | 0.01% | 524 |
|
|
2022
Q4 | $2.09M | Sell |
13,389
-26,580
| -67% | -$3.82M | 0.01% | 490 |
|
|
2022
Q3 | $4.9M | Buy |
39,969
+31,776
| +388% | +$4.18M | 0.07% | 154 |
|
|
2022
Q2 | $1.09M | Sell |
8,193
-16,287
| -67% | -$2.22M | 0.01% | 517 |
|
|
2022
Q1 | $3.35M | Sell |
24,480
-10,759
| -31% | -$1.5M | 0.03% | 325 |
|
|
2021
Q4 | $6.1M | Sell |
35,239
-32,609
| -48% | -$4.96M | 0.03% | 239 |
|
|
2021
Q3 | $9.86M | Buy |
67,848
+58,778
| +648% | +$8.6M | 0.07% | 193 |
|
|
2021
Q2 | $1.2M | Sell |
9,070
-3,657
| -29% | -$479K | 0.01% | 518 |
|
|
2021
Q1 | $1.63M | Sell |
12,727
-12,105
| -49% | -$1.49M | 0.01% | 488 |
|
|
2020
Q4 | $2.96M | Buy |
24,832
+8,654
| +53% | +$1.05M | 0.01% | 481 |
|
|
2020
Q3 | $1.85M | Buy |
16,178
+3,030
| +23% | +$358K | 0.02% | 434 |
|
|
2020
Q2 | $1.5M | Buy |
13,148
+3,290
| +33% | +$349K | 0.02% | 445 |
|
|
2020
Q1 | $792K | Sell |
9,858
-6,070
| -38% | -$628K | 0.01% | 485 |
|
|
2019
Q4 | $1.7M | Sell |
15,928
-32,505
| -67% | -$3.39M | 0.01% | 610 |
|
|
2019
Q3 | $5.18M | Buy |
48,433
+17,729
| +58% | +$1.82M | 0.05% | 339 |
|
|
2019
Q2 | $3.13M | Sell |
30,704
-1,435
| -4% | -$138K | 0.02% | 501 |
|
|
2019
Q1 | $2.89M | Sell |
32,139
-11,993
| -27% | -$1.04M | 0.02% | 454 |
|
|
2018
Q4 | $3.67M | Buy |
44,132
+6,342
| +17% | +$595K | 0.03% | 369 |
|
|
2018
Q3 | $4.08M | Sell |
37,790
-38,794
| -51% | -$4.25M | 0.03% | 391 |
|
|
2018
Q2 | $8.42M | Buy |
76,584
+51,439
| +205% | +$5.36M | 0.07% | 267 |
|
|
2018
Q1 | $2.52M | Sell |
25,145
-5,330
| -17% | -$546K | 0.03% | 447 |
|
|
2017
Q4 | $3M | Buy |
30,475
+9,477
| +45% | +$898K | 0.02% | 453 |
|
|
2017
Q3 | $1.97M | Buy |
20,998
+1,657
| +9% | +$176K | 0.02% | 448 |
|
|
2017
Q2 | $2.15M | Buy |
19,341
+4,978
| +35% | +$526K | 0.02% | 448 |
|
|
2017
Q1 | $1.41M | Buy |
14,363
+4,888
| +52% | +$466K | 0.01% | 448 |
|
|
2016
Q4 | $871K | Buy |
+9,475
| New | +$817K | 0.01% | 439 |
|
Other funds holding DGX
CIBC World Markets's DGX Position: Q4 2025 in Review
CIBC World Markets opened a new position in Quest Diagnostics (DGX) in Q4 2025: 18,667 shares worth $3.24M. The stake represents 0.02% of the portfolio and ranks #513 among its holdings. This is a return to the name: CIBC World Markets previously reported a position in DGX as recently as Q2 2025.
CIBC World Markets first reported a position in DGX in Q4 2016 and has held it in 36 quarters since. The position peaked at $9.86M in Q3 2021. 1,048 funds tracked by Wall St. Rank hold DGX as of Q4 2025.
- CIBC World Markets held 18,667 shares of Quest Diagnostics worth $3.24M as of Q4 2025.
- Quest Diagnostics was a new CIBC World Markets position in Q4 2025.
- Quest Diagnostics made up 0.02% of CIBC World Markets's portfolio in Q4 2025, its #513 holding.
- CIBC World Markets first reported a position in Quest Diagnostics in Q4 2016 and has held it in 36 quarters since.
- CIBC World Markets's Quest Diagnostics position peaked at $9.86M in Q3 2021.
- 1,048 funds tracked by Wall St. Rank held Quest Diagnostics as of Q4 2025.
Based on CIBC World Markets's 13F filing for Q4 2025, filed 12 Feb 2026.